MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:41Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Lipid-lowering agents]]
			[[Category:B-vitamins]]
			[[Category:Vitamins]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #288

2026-05-23T04:08:52Z

parser-claude batch MedTemplate pre-fill, Top 300 #288

New page

{{MedTemplate
| generic = Niacin (nicotinic acid, vitamin B3)
| brand = Niaspan (ER, Rx), Niacor (IR, Rx); huge OTC presence
| structure =
| classes = [[:Category:Lipid-lowering_agents|Lipid-lowering agent]], [[:Category:B-vitamins|B-vitamin]], [[:Category:Vitamins|Vitamin]]
| uses = <vote slug="hyperlipidemia-use">Hyperlipidemia (HDL raising, triglyceride lowering — though clinical outcome benefit not demonstrated in modern trials)</vote>, <vote slug="pellagra-use">Pellagra (vitamin B3 deficiency)</vote>, <vote slug="hyperphosphatemia-ckd-use">Hyperphosphatemia in CKD (off-label, modest)</vote>
| starting_dose = Niaspan ER 500 mg PO at bedtime, titrate weekly to 1-2 g/d; flushing-protective aspirin 30-60 minutes before dose; pellagra replacement 100-500 mg/d
| preparations = OTC IR niacin 50-500 mg tablets; Niaspan ER 500, 750, 1000 mg tablets; "no-flush" niacin (inositol hexaniacinate, lacks evidence)
| fda_max = 2 g/d (Niaspan); higher off-label use historical
| pill_id =
| routes = Oral
| onset = Lipid changes 4-8 weeks
| duration = 24 hours
| halflife = ~1 hour (IR niacin); ER formulations extend functional duration<ref name="niaspan-label">FDA Prescribing Information, Niaspan (niacin ER), AbbVie, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020381s057lbl.pdf</ref>
| bioavailability = High (oral; food enhances)<ref name="niaspan-label" />
| pregnancy = Pharmacologic doses generally avoided in pregnancy; vitamin doses fine.{{citation needed}}
| legal = OTC (low-dose, dietary supplement) and [[USLegal:Prescription only|Rx-only]] (Niaspan ER) in US
| mechanism = <vote slug="niacin-mech-claim">Niacin in pharmacologic doses binds the GPR109A (HCA2) receptor on adipocytes, inhibiting hormone-sensitive lipase and decreasing free fatty acid release; the consequent reduction in hepatic substrate for VLDL synthesis lowers triglycerides and LDL, while a separate mechanism raises HDL.</vote> The AIM-HIGH (2011) and HPS2-THRIVE (2014) trials showed that adding niacin to statin therapy does not reduce cardiovascular events despite lipid changes, substantially reducing its modern use. Flushing (GPR109A-mediated PGD2 release in skin) is the universal adverse effect; aspirin pretreatment and ER formulations reduce but do not eliminate it<ref name="niaspan-label" />.
}}

== References ==
<references />

Niacin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #288